title: Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'.
authors.affiliation: Heartland Health Outreach, Chicago, IL, USA. mdoesimkins@gmail.com.
authors.forename: Maya
authors.initials: M
authors.lastname: Doe-Simkins
authors.affiliation: University of Washington, Alcohol and Drug Abuse Institute, Seattle, WA, USA.
authors.forename: Caleb
authors.initials: C
authors.lastname: Banta-Green
authors.affiliation: Network for Public Health Law, Southeastern Region, Chapel Hill, NC, USA.
authors.forename: Corey S
authors.initials: CS
authors.lastname: Davis
authors.affiliation: Boston Medical Center, CARE Unit, General Internal Medicine, Boston, MA, USA.
authors.forename: Traci C
authors.initials: TC
authors.lastname: Green
authors.affiliation: Boston University School of Medicine, Department of Emergency Medicine, Boston, MA, USA.
authors.forename: Alexander Y
authors.initials: AY
authors.lastname: Walley
mesh_terms: D000701:Analgesics, Opioid; D062787:Drug Overdose; D003932:Heroin; D006801:Humans; D009270:Naloxone; D009292:Narcotic Antagonists
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D009270:Naloxone; D003932:Heroin
keywords: Ethics and research; heroin overdose; layperson naloxone; nasal naloxone; off-label use of medicine; opioid overdose; overdose prevention; people who use drugs